SAN

92.24

+0.2%↑

SHL.DE

49.17

-0.1%↓

ARGX

507

+0.8%↑

FRE

43.29

+0.89%↑

ONC.US

233.1

+1.96%↑

SAN

92.24

+0.2%↑

SHL.DE

49.17

-0.1%↓

ARGX

507

+0.8%↑

FRE

43.29

+0.89%↑

ONC.US

233.1

+1.96%↑

SAN

92.24

+0.2%↑

SHL.DE

49.17

-0.1%↓

ARGX

507

+0.8%↑

FRE

43.29

+0.89%↑

ONC.US

233.1

+1.96%↑

SAN

92.24

+0.2%↑

SHL.DE

49.17

-0.1%↓

ARGX

507

+0.8%↑

FRE

43.29

+0.89%↑

ONC.US

233.1

+1.96%↑

SAN

92.24

+0.2%↑

SHL.DE

49.17

-0.1%↓

ARGX

507

+0.8%↑

FRE

43.29

+0.89%↑

ONC.US

233.1

+1.96%↑

Search

Orion Oyj (Class B)

Closed

57.2 0.26

Overview

Share price change

24h

Current

Min

56.55

Max

57.2

Key metrics

By Trading Economics

Income

-12M

61M

Sales

-80M

355M

P/E

Sector Avg

21.996

56.602

EPS

0.44

Dividend yield

2.99

Profit margin

17.287

Employees

3,943

EBITDA

136M

202M

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.99%

2.45%

Market Stats

By TradingEconomics

Market Cap

2.1B

7.7B

Previous open

56.94

Previous close

57.2

Orion Oyj (Class B) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 maj 2025, 20:40 UTC

Acquisitions, Mergers, Takeovers

FedEx Names CEO, Chairman for Planned Freight Spinoff

20 maj 2025, 00:00 UTC

Top News

America's Fiscal Situation Threatens the Good Mood on Wall Street -- WSJ

19 maj 2025, 23:48 UTC

Market Talk

Nikkei May Rise as Fears About Moody's U.S. Downgrade Ease -- Market Talk

19 maj 2025, 23:43 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

19 maj 2025, 22:33 UTC

Market Talk

Uranium Buyers Could Accelerate Restocking -- Market Talk

19 maj 2025, 22:16 UTC

Acquisitions, Mergers, Takeovers

Yuexiu Property to Use Divestment Proceeds for Business Development Purposes

19 maj 2025, 22:16 UTC

Acquisitions, Mergers, Takeovers

Yuexiu Property to Sell Stake for CNY4.15B

19 maj 2025, 22:15 UTC

Acquisitions, Mergers, Takeovers

Yuexiu Property to Sell Stake to China Resources Land

19 maj 2025, 22:15 UTC

Acquisitions, Mergers, Takeovers

Yuexiu Property to Sell 65% Stake in Beijing Haizhen Real Estate

19 maj 2025, 22:02 UTC

Earnings

Trip.com Group 1Q Rev $1.9B >TCOM

19 maj 2025, 22:02 UTC

Earnings

Trip.com Group 1Q Adj EPS 82c >TCOM

19 maj 2025, 22:02 UTC

Earnings

Trip.com Group 1Q EPS 84c >TCOM

19 maj 2025, 21:58 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

19 maj 2025, 21:58 UTC

Market Talk

Global Equities Roundup: Market Talk

19 maj 2025, 21:58 UTC

Market Talk

Automakers to Raise Prices by End of June, Toyota COO Says -- Market Talk

19 maj 2025, 21:50 UTC

Earnings

Home Depot's Earnings Could Mirror a Sluggish Housing Market -- Barrons.com

19 maj 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

19 maj 2025, 20:21 UTC

Acquisitions, Mergers, Takeovers

FedEx: R. Brad Martin, Vice Chmn of the FedEx Corp. Bd of Directors, Agreed to Serve as Chmn of the Bd of FedEx Freight >FDX

19 maj 2025, 20:21 UTC

Acquisitions, Mergers, Takeovers

FedEx: Both Appointments Will Be Effective Upon Completion of the Previously Announced Separation of FedEx Freight From FedEx Corp. >FDX

19 maj 2025, 20:21 UTC

Acquisitions, Mergers, Takeovers

FedEx: Plans for the Spinoff, Which Is Expected to Occur by June 2026, Remain on Track >FDX

19 maj 2025, 20:21 UTC

Acquisitions, Mergers, Takeovers

FedEx: Announces Leadership for Independent FedEx Freight Co Upon Separation

19 maj 2025, 20:21 UTC

Acquisitions, Mergers, Takeovers

FedEx: John A. Smith, Oper Chief, U.S. and Canada, of Federal Express, Has Been Selected as Pres and CEO of FedEx Freight >FDX

19 maj 2025, 20:20 UTC

Top News

Major U.S. Stock Indexes Finish Higher; Dollar Falls -- WSJ

19 maj 2025, 20:15 UTC

Acquisitions, Mergers, Takeovers

U.S. Steel Stock Rises on Report of Better Nippon Offer. Why Trump Could Say 'Yes.' -- Barrons.com

19 maj 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19 maj 2025, 19:59 UTC

Top News

JPMorgan CEO Dimon Still Intends to Step Down in Next Few Years. 'It's Up to the Board.' -- Barrons.com

19 maj 2025, 19:58 UTC

Market Talk

Estonia Redirects Ships After Russia Detains Greek Tanker -- Market Talk

19 maj 2025, 19:52 UTC

Market Talk

Imports Accelerate at Southern California Ports -- Market Talk

19 maj 2025, 19:16 UTC

Market Talk

Oil Futures Edge Up After Shaky Start -- Market Talk

19 maj 2025, 19:00 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Sanmina Shares Fall After Deal to Buy AMD's Newly Acquired Manufacturing Company

Peer Comparison

Price change

Orion Oyj (Class B) Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Orion Oyj (Class B)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.